Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

PHOENIX Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours

Coordinator
Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca, Spain
Runs
1 June 2026 to 31 May 2032
Status
Running
EU funding
€8.5m
Total cost
—
Partners
16 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101289276

What the project is doing

In the project's own words, from its summary on CORDIS.

Childhood cancer is the leading cause of disease-related death in children, with high-risk neuroblastoma and other aggressive paediatric solid tumours representing a critical unmet need. Despite multimodal therapy, over half of children with relapsed or refractory disease do not achieve long-term survival, and those who do often suffer severe, lifelong toxicities. There is an urgent need for safer and more effective therapies.

Ibrilatazar (ABTL0812) is a first-in-class, orally administered anticancer agent that induces tumour cell death through endoplasmic reticulum stress and cytotoxic autophagy. Unlike conventional genotoxic chemotherapies, it spares DNA, offering a potentially safer profile highly relevant in children. In adult patients with advanced solid tumours, ibrilatazar has shown an excellent safety record and early efficacy in Phase I/II trials, with long-term stabilisation in heavily pre-treated patients, thereby supporting its evaluation in the paediatric population.

Preclinical studies in neuroblastoma models, including MYCN-amplified and chemoresistant cell lines, demonstrate that ibrilatazar reduces tumour growth, downregulates MYCN expression, and enhances standard chemotherapies and differentiating agents. Building on this evidence, PHOENIX will conduct a first-in-child, multicentre Phase I/II clinical trial of ibrilatazar in relapsed/refractory neuroblastoma and other aggressive solid tumours.

The trial will test combinations with irinotecan-temozolomide and selected immunotherapies (anti-GD2, anti-VEGF), aligned with our preclinical findings. In parallel, a comprehensive translational programme will integrate pharmacokinetic, pharmacodynamic, genomic, and immunological biomarker studies, aiming to enable patient stratification, early treatment monitoring, and improved trial inclusiveness by addressing social determinants of health.

Thus, PHOENIX seeks to deliver a safer, more effective therapeutic alternative for children with high-risk cancers. This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment - innovative clinical trials for paediatric cancer.

Who is involved

OrganisationCityCountryRole
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainCoordinator
Fakultni Nemocnice BrnoBrnoCzechiaParticipant
Masarykova univerzitaBrnoCzechiaThird party
Region HovedstadenHillerodDenmarkParticipant
Ability Pharmaceuticals SABarcelonaSpainParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La PazMadridSpainThird party
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino JesusMadridSpainParticipant
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainThird party
Fundación CRIS de Investigación para Vencer el CáncerMadridSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Institut CurieParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Children's Health IrelandDublinIrelandParticipant
Echalliance Company Limited by GuaranteeDublinIrelandParticipant
Shine 2europe LdaCoimbraPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI